TY - JOUR
T1 - Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED
AU - Garkal, Atul
AU - Bangar, Priyanka
AU - Rajput, Amarjitsing
AU - Pingale, Prashant
AU - Dhas, Namdev
AU - Sami, Anam
AU - Mathur, Khushboo
AU - Joshi, Shubham
AU - Dhuri, Sonika
AU - Parikh, Dhaivat
AU - Mutalik, Srinivas
AU - Mehta, Tejal
N1 - Funding Information:
The authors would like to thank Nirma University for providing financial assistance in the form of Nirma University fellowship-SRF to Atul Garkal (NU/Ph.D./IP/GAD /19-20/1496). The authors would like to thank Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, for providing the necessary facilities.
Publisher Copyright:
© 2022
PY - 2022/10
Y1 - 2022/10
N2 - The invigoration of protein and peptides in serious eye disease includes age-related macular degeneration, choroidal neovascularization, retinal neovascularization, and diabetic retinopathy. The transportation of macromolecules like aptamers, recombinant proteins, and monoclonal antibodies to the posterior segment of the eye is challenging due to their high molecular weight, rapid degradation, and low solubility. Moreover, it requires frequent administration for prolonged therapy. The long-acting novel formulation strategies are helpful to overcome these issues and provide superior therapy. It avoids frequent administration, improves stability, high retention time, and avoids burst release. This review briefly enlightens posterior segments of eye diseases with their diagnosis techniques and treatments. This article mainly focuses on recent advanced approaches like intravitreal implants and injectables, electrospun injectables, 3D printed drug-loaded implants, nanostructure thin-film polymer devices encapsulated cell technology-based intravitreal implants, injectable and depots, microneedles, PDS with ranibizumab, polymer nanoparticles, inorganic nanoparticles, hydrogels and microparticles for delivering macromolecules in the eye for intended therapy. Furthermore, novel techniques like aptamer, small Interference RNA, and stem cell therapy were also discussed. It is predicted that these systems will make revolutionary changes in treating posterior segment eye diseases in future.
AB - The invigoration of protein and peptides in serious eye disease includes age-related macular degeneration, choroidal neovascularization, retinal neovascularization, and diabetic retinopathy. The transportation of macromolecules like aptamers, recombinant proteins, and monoclonal antibodies to the posterior segment of the eye is challenging due to their high molecular weight, rapid degradation, and low solubility. Moreover, it requires frequent administration for prolonged therapy. The long-acting novel formulation strategies are helpful to overcome these issues and provide superior therapy. It avoids frequent administration, improves stability, high retention time, and avoids burst release. This review briefly enlightens posterior segments of eye diseases with their diagnosis techniques and treatments. This article mainly focuses on recent advanced approaches like intravitreal implants and injectables, electrospun injectables, 3D printed drug-loaded implants, nanostructure thin-film polymer devices encapsulated cell technology-based intravitreal implants, injectable and depots, microneedles, PDS with ranibizumab, polymer nanoparticles, inorganic nanoparticles, hydrogels and microparticles for delivering macromolecules in the eye for intended therapy. Furthermore, novel techniques like aptamer, small Interference RNA, and stem cell therapy were also discussed. It is predicted that these systems will make revolutionary changes in treating posterior segment eye diseases in future.
UR - http://www.scopus.com/inward/record.url?scp=85137157906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137157906&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2022.08.040
DO - 10.1016/j.jconrel.2022.08.040
M3 - Review article
C2 - 36030993
AN - SCOPUS:85137157906
SN - 0168-3659
VL - 350
SP - 538
EP - 568
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -